All In MedTech

Device Trial Radar · NCT07764874

Unilateral and Staged Bilateral Pallidothalamic Tractotomy Using Exablate MRgFUS in Advanced Parkinson's Disease.

An MR Guided Focused Ultrasound (MRgFUS) Randomized Trial Using the Exablate Neuro System to Assess the Effectiveness and Safety Outcomes of Unilateral and Staged Bilateral Ablation in the Subthalamic Region Involving the Pallidothalamic Tract (PTT) in Advanced Parkinson's Disease (PD) With Motor Complications.

Last checked: Nov 20, 2026Latest source record: Nov 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2029

Study completion Jun 2031

Sponsor

Lead sponsor
InSightecNot on our public-company list
Sponsor type
Industry
First posted
Aug 14, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Sequential
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 30 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a randomized clinical trial evaluating a focused ultrasound treatment for people with advanced Parkinson's disease (PD) who have disabling motor complications and symptoms. The study uses the Exablate Neuro System, which delivers MR-guided Focused Ultrasound (MRgFUS). This technology focuses ultrasound energy on a specific brain target and generates heat to create a small lesion (ablation) without making a surgical incision. The target in this study is the Pallidothalamic Tract (PTT), a pathway involved in the abnormal brain circuits that contribute to Parkinson's symptoms and complications. This study is evaluating whether treating one side of the brain or treating both sides (in separate procedures) provides better outcomes for people with advanced Parkinson's disease who have motor complications and symptoms. The main outcome measure is the change in the MDS-UPDRS Part III Upper/Lower Extremity (ULE) score at 3 months after first and second side treatment, compared with the respective control groups. MDS-UPDRS Part III is a standard clinical scale used to assess Parkinson's motor symptoms. ULE score focuses on motor function in the arms and legs. Assessments are performed in the OFF-medication state, meaning Parkinson's medications are temporarily withheld so that the treatment effect can be measured more accurately. In addition improvement in motor complications will be assessed with MDS-UPDRS Part IV and Patient diaries.

Conditions

  • Parkinson Disease

Interventions

  • Unilateral Exablate MRgFUS Pallidothalamic TractotomyDevice

    1st side Exablate MRgFUS Pallidothalamic Tractotomy for Parkinson's Disease

  • Staged Bilateral Exablate Pallidothalamic TractotomyDevice

    2nd side staged Exablate MRgFUS Pallidothalamic Tractotomy for Parkinson's Disease

  • Best Medical Treatment (BMT)Drug

    Subjects will be managed according to conventional therapeutic guidelines (i.e., best medical treatment) for Parkinson's Disease

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. MDS-UPRDS Part III ULE score in the OFF-medication (unilateral treatment)Time frame: 3 Months
  2. MDS-UPRDS Part III ULE score in the OFF-medication (bilateral treatment)Time frame: 3 Months

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Anam Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.